183 related articles for article (PubMed ID: 31085753)
1. Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.
Abu Zaid M; Dinh PC; Monahan PO; Fung C; El-Charif O; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Cook R; Althouse S; Ardeshir-Rouhani-Fard S; Sesso HD; Huddart R; Mushiroda T; Kubo M; Dolan ME; Einhorn LH; Fossa SD; Travis LB;
J Natl Compr Canc Netw; 2019 May; 17(5):459-468. PubMed ID: 31085753
[TBL] [Abstract][Full Text] [Related]
2. Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study.
ArdeshirRouhaniFard S; Dinh PC; Monahan PO; Fossa SD; Huddart R; Fung C; Song Y; Feldman DR; Hamilton RJ; Vaughn DJ; Martin NE; Kollmannsberger C; Einhorn L; Kroenke K; Travis LB
Cancer Epidemiol Biomarkers Prev; 2021 Jun; 30(6):1129-1138. PubMed ID: 33849970
[TBL] [Abstract][Full Text] [Related]
3. Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.
Fung C; Sesso HD; Williams AM; Kerns SL; Monahan P; Abu Zaid M; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Kollmannsberger CK; Cook R; Althouse S; Ardeshir-Rouhani-Fard S; Lipshultz SE; Einhorn LH; Fossa SD; Travis LB;
J Clin Oncol; 2017 Apr; 35(11):1211-1222. PubMed ID: 28240972
[TBL] [Abstract][Full Text] [Related]
4. High risk of hypogonadism in young male cancer survivors.
Isaksson S; Bogefors K; Ståhl O; Eberhard J; Giwercman YL; Leijonhufvud I; Link K; Øra I; Romerius P; Bobjer J; Giwercman A
Clin Endocrinol (Oxf); 2018 Mar; 88(3):432-441. PubMed ID: 29245176
[TBL] [Abstract][Full Text] [Related]
5. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.
Kerns SL; Fung C; Monahan PO; Ardeshir-Rouhani-Fard S; Abu Zaid MI; Williams AM; Stump TE; Sesso HD; Feldman DR; Hamilton RJ; Vaughn DJ; Beard C; Huddart RA; Kim J; Kollmannsberger C; Sahasrabudhe DM; Cook R; Fossa SD; Einhorn LH; Travis LB;
J Clin Oncol; 2018 May; 36(15):1505-1512. PubMed ID: 29617189
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors.
Zaid MA; Gathirua-Mwangi WG; Fung C; Monahan PO; El-Charif O; Williams AM; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Cook R; Althouse SK; Ardeshir-Rouhani-Fard S; Dinh PC; Sesso HD; Einhorn LH; Fossa SD; Travis LB;
J Natl Compr Canc Netw; 2018 Mar; 16(3):257-265. PubMed ID: 29523664
[No Abstract] [Full Text] [Related]
7. The effects of hypogonadism on quality of life in survivors of germ cell tumors treated with surgery alone versus surgery plus platinum-based chemotherapy.
Khanal N; Ahmed SS; Kalra M; Miller TJ; Brames MJ; Stump TE; Monahan P; Hanna NH; Einhorn LH
Support Care Cancer; 2020 Jul; 28(7):3165-3170. PubMed ID: 31707501
[TBL] [Abstract][Full Text] [Related]
8. Low-grade inflammation in survivors of childhood cancer and testicular cancer and its association with hypogonadism and metabolic risk factors.
Ekedahl H; Isaksson S; Ståhl O; Bogefors K; Romerius P; Eberhard J; Giwercman A
BMC Cancer; 2022 Feb; 22(1):157. PubMed ID: 35135482
[TBL] [Abstract][Full Text] [Related]
9. Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.
Hjelle LV; Bremnes RM; Gundersen POM; Sprauten M; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Oldenburg J; Haugnes HS
Urol Oncol; 2016 Nov; 34(11):487.e13-487.e20. PubMed ID: 27523611
[TBL] [Abstract][Full Text] [Related]
10. Risk of low bone mineral density in testicular germ cell cancer survivors: association with hypogonadism and treatment modality.
Isaksson S; Bogefors K; Åkesson K; Egund L; Bobjer J; Leijonhufvud I; Giwercman A
Andrology; 2017 Sep; 5(5):898-904. PubMed ID: 28591464
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of hypogonadism determined by serum free testosterone level in Japanese testicular cancer survivors.
Kurobe M; Kawai K; Suetomi T; Iwamoto T; Waku N; Kawahara T; Kojima T; Joraku A; Miyazaki J; Nishiyama H
Int J Urol; 2018 May; 25(5):457-462. PubMed ID: 29478250
[TBL] [Abstract][Full Text] [Related]
12. Adverse health outcomes and global quality of life in long-term testicular cancer survivors: a longitudinal 30-year perspective.
Fosså SD; Haugnes HS; Dahl AA; Kiserud CE; Fosså A; Skalleberg J; Myklebust TÅ
Ann Oncol; 2023 Dec; 34(12):1165-1174. PubMed ID: 37739265
[TBL] [Abstract][Full Text] [Related]
13. Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy.
Stelwagen J; Lubberts S; Steggink LC; Steursma G; Kruyt LM; Donkerbroek JW; van Roon AM; van Gessel AI; van de Zande SC; Meijer C; Gräfin Zu Eulenburg CH; Oosting SF; Nuver J; Walenkamp AME; Jan de Jong I; Lefrandt JD; Gietema JA
Br J Cancer; 2020 Nov; 123(11):1599-1607. PubMed ID: 32921790
[TBL] [Abstract][Full Text] [Related]
14. Arterial elasticity as a risk factor for early cardiovascular disease among testicular cancer survivors treated with platinum-based chemotherapy: a cross-sectional pilot study.
Blaes AH; Mulrooney DA; Vogel RI; Solovey A; Hebbel R; Peterson BA; Neglia JP; Biewen C; Konety SH; Duprez DA
Vasc Health Risk Manag; 2018; 14():205-211. PubMed ID: 30237722
[TBL] [Abstract][Full Text] [Related]
15. Sexual function in men treated for testicular cancer.
Eberhard J; Ståhl O; Cohn-Cedermark G; Cavallin-Ståhl E; Giwercman Y; Rylander L; Eberhard-Gran M; Kvist U; Fugl-Meyer KS; Giwercman A
J Sex Med; 2009 Jul; 6(7):1979-89. PubMed ID: 19453896
[TBL] [Abstract][Full Text] [Related]
16. Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score.
Feldman DR; Ardeshir-Rouhani-Fard S; Monahan P; Sesso HD; Fung C; Williams AM; Hamilton RJ; Vaughn DJ; Beard CJ; Cook R; Zaid MA; Lipshultz SE; Einhorn LH; Oeffinger KC; Travis LB; Fossa SD;
Clin Genitourin Cancer; 2018 Aug; 16(4):e761-e769. PubMed ID: 29534941
[TBL] [Abstract][Full Text] [Related]
17. Emotional disorders in testicular cancer survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality.
Eberhard J; Ståhl O; Cohn-Cedermark G; Cavallin-Ståhl E; Giwercman Y; Rastkhani H; Rylander L; Eberhard-Gran M; Kvist U; Giwercman A
J Affect Disord; 2010 May; 122(3):260-6. PubMed ID: 19656574
[TBL] [Abstract][Full Text] [Related]
18. Taste and smell function in testicular cancer survivors treated with cisplatin-based chemotherapy in relation to dietary intake, food preference, and body composition.
IJpma I; Renken RJ; Gietema JA; Slart RH; Mensink MG; Lefrandt JD; Ter Horst GJ; Reyners AK
Appetite; 2016 Oct; 105():392-9. PubMed ID: 27298084
[TBL] [Abstract][Full Text] [Related]
19. Androgen deficiency symptoms in testicular cancer survivors are associated with sexual problems but not with serum testosterone or therapy.
Lackner JE; Koller A; Schatzl G; Marberger M; Kratzik C
Urology; 2009 Oct; 74(4):825-9. PubMed ID: 19589582
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.
Dolan ME; El Charif O; Wheeler HE; Gamazon ER; Ardeshir-Rouhani-Fard S; Monahan P; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Fung C; Kim J; Fossa SD; Hertz DL; Mushiroda T; Kubo M; Einhorn LH; Cox NJ; Travis LB;
Clin Cancer Res; 2017 Oct; 23(19):5757-5768. PubMed ID: 28611204
[No Abstract] [Full Text] [Related]
[Next] [New Search]
